



## August Newsletter 2022

---

### Congratulations Professor Judith Trotman!



We would like to warmly congratulate ClinTrial Refer co-founder Professor Judith Trotman on being the newly elected Chair of the Australian Leukaemia and Lymphoma Group (ALLG) Scientific Advisory Committee (SAC). Judith is a 22 year member who will be the first kiwi and female Chair of the SAC!

Judith is the Founding Director of the Clinical Research Unit at Concord Hospital (Sydney) 2005 -2019 and she is currently the Head of Department, Haematology at Concord Hospital. She provides global leadership in charting the role of PET scanning in lymphoma and, based on her data, was successful in obtaining an MBS listing of PET for indolent lymphomas.

Professor Trotman is a clinician researcher who is passionate about embedding clinical research into quality care and we are super proud of her amazing work and this excellent new appointment. Congratulations!

---

### Trial Spotlight



## Trial Spotlight



On average 28 trials are listed in the ClinTrial Refer database every month

**We aim to highlight some of these in our newsletter each month**

Search CTR website



The PRIME:PsO Study A Clinical Research Opportunity for Adults with Moderate Plaque Type Psoriasis



What is the PRIME:PsO Study?

The PRIME:PsO Study is a clinical research study evaluating the use of an investigational medication, called KBL697, in people with moderate plaque type psoriasis. Psoriasis is a long-lasting autoimmune disease. Plaque type psoriasis is characterized by raised red, dry, and itchy skin, called plaques.

What will the PRIME:PsO Study look at?

The PRIME:PsO Study will assess the safety of KBL697, and also measure how the body

responds to this treatment. The PRIME:PsO Study will enroll around 80 individuals with moderate plaque type psoriasis in around 10 centres in the USA and Australia.

What does taking part mean for me?

If you join the study, you will need to attend the study centre a minimum of 7 times to have some tests and assessments, including:

- Routine medical tests
- Overall health checks
- Checking the signs and symptoms of your psoriasis.

As well as clinic visits, you will also be asked to complete some diaries to document any additional medications you have taken, your study medication intake, and any side-effects you may have experienced while taking the study medication.

Can I take part in this study?

You may be able to take part in the PRIME:PsO Study if you

- \*are aged 18 to 75 years
- have had plaque type psoriasis of moderate severity for at least 6 months

\*There are other criteria that you will need to meet to qualify for the PRIME:PsO Study; the study team will discuss these with you.

Click [here](#) to learn more.

---

## ClinTrial Refer App Features


We are always listening to user feedback and making changes to improve the search experience for our users.

We have just added a new health condition to the Oncology filter labelled 'Symptom Management'. This new condition will now contain trials that study Oncology related symptoms (such as nausea, mental distress, constipation, etc). This additional filter will separate Oncology treatment trials from those aimed at managing Oncology symptoms to deliver more relevant results to the user. We have also updated the existing Supportive Care - it is now "Supportive Care (miscellaneous)". This is the section for those non-symptom and non-treatment trials such as new e-Health programs or PROMS and survivorship research etc.

We have also updated Multiple Myeloma in the Haematology filter. You can now search for Multiple Myeloma according to 'Newly diagnosed non-transplant eligible', 'Newly diagnosed transplant eligible', and 'Relapsed / Refractory'.

We trust this will be helpful to many of our users. Please contact us if you would like to feedback any suggestions.

Contact: [christine.zahren@health.nsw.gov.au](mailto:christine.zahren@health.nsw.gov.au)



There are new categories under the condition of Multiple Myeloma.

There is a new Oncology health condition called Symptom Management.

Oncology: Supportive Care has been streamlined and updated.

## Walking fundraiser kick starts new melanoma trial



A community fundraising campaign has donated \$100,000 to support a clinical trial aimed at improving the care, treatment and quality of life for patients with melanoma that has spread to the brain.

The trial, led by A/Prof Tim Wei Wang from Westmead Hospital and the University of Sydney, and Dr Malaka Ameratunga from the Alfred Hospital and Monash University, will

focus on testing a new treatment combination in patients with symptomatic melanoma brain metastases.

Once melanoma spreads to the brain, patients often have a poor prognosis and a short life expectancy, although advances in treatment – including those pioneered by Australian researchers – are providing real hope.

Now that the generous funding from the ASCF has been received, work on the Melanoma Brain Metastases Clinical Trial (known as the BETTER trial) will initially begin at the Westmead and Alfred Hospitals.

"If the initial trial is successful, we hope to expand it into a larger trial supported by further funding. This will allow us to increase the number of patients who can participate in the research and open additional recruiting sites, as well as add more investigators from Australia and overseas to boost the trial" , stated A/Prof Wang (BETTER, Trial Investigator).

Keep an eye out in the [ClinTrial Refer](#) database and MASC App for updates on the BETTER trial or visit the MASC [website](#).

---

## GESA Annual Gastroenterology Week (AGW)



GESA Annual Gastroenterology Week (AGW) is the premier annual gastroenterology and hepatology professional meeting in Australia.

Conference details: Friday 9 to Sunday 11 September 2022 at the ICC in Sydney NSW

This year's program will feature sessions complementing the meeting's theme: Bidirectional Learning – a foundation for excellence & innovation. This theme recognises the importance of mutual learning and sharing of ideas, with the purpose of achieving clinical excellence in Gastroenterology and Hepatology. Bidirectional learning is not just about peer relationships but also understanding our patients' journeys and lived experience through their illness. The latest scientific and clinical developments and innovations in the management of gastroenterological and liver conditions will be presented in the first Face-to-Face AGW for over two years with the additional capacity for online participation for those unable to attend in person.

Register here: [AGW Registration - GESA AGW](#)

GESA is CinTrial Refer partner and they are currently communicating 91 trials in the ClinTrial Refer database. Download the ClinTrial Refer App or visit the ClinTrial Refer website to start searching today- [www.clintrialrefer.org.au](http://www.clintrialrefer.org.au)

---

## Do you have something to share?

Share your story if you have taken part in a clinical trial or supported someone through a trial. Your stories and thoughts are important to us and can be a great encouragement to others. If you'd like to share a clinical trial story please email us at [admin@clintrialreferapp.com](mailto:admin@clintrialreferapp.com). We'd love to hear from you.



---

ADDRESS

ClinTrial Refer c/o Ground Floor,  
W R Pitney Building, St George Hospital,  
Gray Street, KOGARAH 2217  
Australia

EMAIL

[www.clintrialrefer.org.au/](http://www.clintrialrefer.org.au/)  
[admin@clintrialreferapp.com](mailto:admin@clintrialreferapp.com)

---

[Unsubscribe](#)

Copyright © \*2019\* \*ClinTrial Refer\*, All rights reserved.

This email was sent to <<Email Address>>  
[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)  
ClinTrialRefer · St George Hospital · Gray Street · Kogarah, Nsw 2017 · Australia